|
|
Blood, 15 August 2007, Vol. 110, No. 4, pp. 1168-1177.
Prepublished online as a Blood First Edition Paper on April 10, 2007; DOI 10.1182/blood-2007-01-066282.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Regulation of COX-2–mediated signaling by  3 type IV noncollagenous domain in tumor angiogenesis
Chandra Shekhar Boosani1,
Arjuna P. Mannam2,
Dominic Cosgrove3,
Rita Silva4,
Kairbaan M. Hodivala-Dilke4,
Venkateshwar G. Keshamouni5, and
Akulapalli Sudhakar1,6,7
1 Cell Signaling and Tumor Angiogenesis Laboratory, Department of Genetics, Boys Town National Research Hospital, Omaha, NE;
2 Department of Neurology, University of Connecticut School of Medicine, Hartford Hospital;
3 Gene Expression Laboratory, Department of Genetics, Boys Town National Research Hospital, Omaha, NE;
4 Cancer Research UK, Cell Adhesion and Disease Laboratory, Richard Dimbleby Department of Cancer Research, St Thomas' Hospital, London, United Kingdom;
5 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor;
6 Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE;
7 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha
Human  3 chain, a noncollagenous domain of type IV collagen [3(IV)NC1], inhibits angiogenesis and tumor growth. These biologic functions are partly attributed to the binding of 3(IV)NC1 to Vβ3 and 3β1 integrins. 3(IV)NC1 binds Vβ3 integrin, leading to translation inhibition by inhibiting focal adhesion kinase/phosphatidylinositol 3-kinase/Akt/mTOR/4E-BP1 pathways. In the present study, we evaluated the role of 3β1 and Vβ3 integrins in tube formation and regulation of cyclooxygenase-2 (COX-2) on 3(IV)NC1 stimulation. We found that although both integrins were required for the inhibition of tube formation by 3(IV)NC1 in endothelial cells, only 3β1 integrin was sufficient to regulate COX-2 in hypoxic endothelial cells. We show that binding of 3(IV)NC1 to 3β1 integrin leads to inhibition of COX-2–mediated pro-angiogenic factors, vascular endothelial growth factor, and basic fibroblast growth factor by regulating I B/NFB axis, and is independent of Vβ3 integrin. Furthermore, β3 integrin–null endothelial cells, when treated with 3(IV)NC1, inhibited hypoxia-mediated COX-2 expression, whereas COX-2 inhibition was not observed in 3 integrin–null endothelial cells, indicating that regulation of COX-2 by 3(IV)NC1 is mediated by integrin 3β1. Our in vitro and in vivo findings demonstrate that 3β1 integrin is critical for 3(IV)NC1-mediated inhibition of COX-2–dependent angiogenic signaling and inhibition of tumor progression.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. S. Boosani, N. Nalabothula, V. Munugalavadla, D. Cosgrove, V. G. Keshamoun, N. Sheibani, and A. Sudhakar
FAK and p38-MAP Kinase-Dependent Activation of Apoptosis and Caspase-3 in Retinal Endothelial Cells by {alpha}1(IV)NC1
Invest. Ophthalmol. Vis. Sci.,
October 1, 2009;
50(10):
4567 - 4575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Silva, G. D'Amico, K. M. Hodivala-Dilke, and L. E. Reynolds
Integrins: The Keys to Unlocking Angiogenesis
Arterioscler Thromb Vasc Biol,
October 1, 2008;
28(10):
1703 - 1713.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
